Biophytis (EPA:ALBPS) | WebDisclosure

Basculer en Français

11062	Companies
242635	Keywords
170874	Articles
130592	Press releases

Home
Companies
Biophytis

PRESS RELEASE

published on 06/20/2024 at 07:00, 2 years 3 months ago

Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 Million
Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 million. Agreement includes upfront and milestones payments, double-digit royalties, and collaboration on manufacturing and clinical development

Biophytis Latin America Exclusive Rights Blanver Pharmaceutical Deal
PRESS RELEASE

published on 06/20/2024 at 07:00, 2 years 3 months ago

Biophytis accorde à Blanver les droits exclusifs de BIO101 en Amérique Latine dans un accord pouvant atteindre 108 M€
Biophytis accorde à Blanver les droits exclusifs de BIO101 en Amérique Latine dans un accord pouvant atteindre 108 M€. Accord de licence exclusive pour la commercialisation de BIO101, y compris dans l’obésité et les infections respiratoires

Biophytis Accord BIO101 Blanver Am\u00e9rique Latine
REGULATED PRESS RELEASE

published on 06/20/2024 at 07:00, 2 years 3 months ago

Biophytis accorde à Blanver les droits exclusifs de BIO101 en Amérique Latine dans un accord pouvant atteindre 108 M€
Biophytis accorde à Blanver les droits exclusifs de BIO101 en Amérique Latine dans un accord pouvant atteindre 108 M€

Biophytis Amérique Latine Accord De Licence BIO101 Blanver
REGULATED PRESS RELEASE

published on 06/20/2024 at 07:00, 2 years 3 months ago

Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 Million
Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 Million. Collaboration for commercialization and clinical development announced

Biophytis Latin America BIO101 Exclusive Rights Blanver
BRIEF

published on 06/20/2024 at 01:15, 2 years 3 months ago

Biophytis prolonge son contrat avec Atlas pour financer ses activités cliniques

Biophytis Biotechnologie Financement Obligations Convertibles Atlas
BRIEF

published on 06/20/2024 at 01:15, 2 years 3 months ago

Biophytis extends its contract with Atlas to finance its clinical activities

Biophytis Biotechnology Convertible Bonds Funding Atlas
PRESS RELEASE

published on 06/20/2024 at 01:10, 2 years 3 months ago

Biophytis prolonge son contrat avec Atlas pour sécuriser le financement de ses activités
Biophytis prolonge son contrat avec Atlas pour sécuriser le financement de ses activités. Renouvellement de l'accord de financement obligataire pour le lancement de programmes cliniques OBA et MYODA

Contrat Biophytis Financement Atlas OBA
PRESS RELEASE

published on 06/20/2024 at 01:10, 2 years 3 months ago

Biophytis extends its contract with Atlas to secure financing for its business activities
Biophytis extends financing agreement with Atlas, ensures funding for clinical programs OBA in obesity and MYODA in DMD. Details on the contract amendment and risk factors

Biophytis Atlas Financing Agreement Clinical Programs Risk Factors
BRIEF

published on 06/19/2024 at 23:05, 2 years 3 months ago

Biophytis prolonge son contrat avec Atlas pour le financement de ses activités

Biophytis Biotechnologie Financement ORNANE Atlas
BRIEF

published on 06/19/2024 at 23:05, 2 years 3 months ago

Biophytis Extends Financing Contract with Atlas

Biophytis Biotechnology Financing Clinical Trials Atlas

Accesswire

Published on 09/23/2026 at 15:42, 1 hour 39 minutes ago

Global Atomic Announces C$50 Million Public Offering of Units
Published on 09/23/2026 at 14:31, 2 hours 50 minutes ago

First Breach Completes First Untethered Flight of Proprietary Drone Prototype, Advancing American-Made Unmanned Systems Program
Published on 09/23/2026 at 14:30, 2 hours 51 minutes ago

Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
Published on 09/23/2026 at 14:00, 3 hours 21 minutes ago

Integrated Rewards Launches "Celebrate Canadian" Campaign to Connect Canadian Brands with Millions of Consumers
Published on 09/23/2026 at 13:30, 3 hours 51 minutes ago

Engineering Cost Study Validates Commercial-Scale U.S. HPMSM Capital Cost and Establishes EMM Capital Cost for Electric Metals' North Star Manganese Project

View all ACCESSWIRE

EQS Group

Published on 09/23/2026 at 16:55, 25 minutes ago

Bird.com secures $450m financing as it launches communications infrastructure for AI agents
Published on 09/23/2026 at 16:40, 40 minutes ago

Xryma Plc Goes Live on the ECB T2 Real-Time Gross Settlement Network
Published on 09/23/2026 at 16:30, 50 minutes ago

nobilia and Coohom Forge Strategic Global Partnership to Redefine the Future of Kitchen Planning with Spatial Intelligence
Published on 09/23/2026 at 15:42, 1 hour 38 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Published on 09/23/2026 at 15:41, 1 hour 39 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Permanent TSB Group Holdings plc

Les Echos

Published on 09/23/2026 at 08:00, 9 hours 21 minutes ago

Résultats semestriels 2026 - ANR par action : 101,90 €, en progression de 8,18 % - Capitaux propres consolidés : 774,5 M€
Published on 09/22/2026 at 18:10, 23 hours 11 minutes ago

Financial statements - 30 june 2026
Published on 09/22/2026 at 18:00, 23 hours 21 minutes ago

Consolidated results for the first half of 2026 EBITDA : 60,5 M€
Published on 09/22/2026 at 18:00, 23 hours 21 minutes ago

Résultats consolidés du premier semestre 2026 EBITDA : 60,5 M€
Published on 09/22/2026 at 17:45, 23 hours 36 minutes ago

Imerys-09-2026-information-share-capital-and-voting-rights-as-of-31-August-2026

View all LES ECHOS COMFI WIRE